Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
US Department of Justice
Covington
UBS
Express Scripts
Julphar

Generated: July 23, 2019

DrugPatentWatch Database Preview

Patent: 6,177,074

Try a free trialSee Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,177,074
Title: Polyethylene glycol modified interferon therapy
Abstract:A method comprising administering a PEG.sub.12000 -IFN alpha conjugate to an individual afflicted with a viral infection susceptible of treatment with interferon alpha, preferably chronic hepatitis C, is disclosed.
Inventor(s): Glue; Paul (Flemington, NJ), Cutler; David L. (Morristown, NJ), Affrime; Melton B. (Flemington, NJ)
Assignee: Schering Corporation (Kenilworth, NJ)
Application Number:09/281,401
Patent Claims:see list of patent claims

Details for Patent 6,177,074

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source
Schering SYLATRON peginterferon alfa-2b VIAL 103949 011 2001-01-19 ➤ Sign Up Schering Corporation (Kenilworth, NJ) ➤ Sign Up RX Orphan company
Schering SYLATRON peginterferon alfa-2b VIAL 103949 010 2001-01-19 ➤ Sign Up Schering Corporation (Kenilworth, NJ) ➤ Sign Up RX Orphan company
Schering SYLATRON peginterferon alfa-2b VIAL 103949 009 2001-01-19 ➤ Sign Up Schering Corporation (Kenilworth, NJ) ➤ Sign Up RX Orphan company
Schering PEGINTRON peginterferon alfa-2b SYRINGE 103949 008 2001-01-19 ➤ Sign Up Schering Corporation (Kenilworth, NJ) ➤ Sign Up RX Orphan company
Schering PEGINTRON peginterferon alfa-2b SYRINGE 103949 007 2001-01-19 ➤ Sign Up Schering Corporation (Kenilworth, NJ) ➤ Sign Up RX Orphan company
Schering PEGINTRON peginterferon alfa-2b SYRINGE 103949 006 2001-01-19 ➤ Sign Up Schering Corporation (Kenilworth, NJ) ➤ Sign Up RX Orphan company
Schering PEGINTRON peginterferon alfa-2b SYRINGE 103949 005 2001-01-19 ➤ Sign Up Schering Corporation (Kenilworth, NJ) ➤ Sign Up RX Orphan company
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Patent Expiration Status Orphan Source

Subscribe to access the full database, or try a Free Trial

International Patent Family for US Patent 6,177,074

Country Patent Number Publication Date
South Africa 9803543 Nov 10, 1998
World Intellectual Property Organization (WIPO) 9716204 May 09, 1997
World Intellectual Property Organization (WIPO) 9848840 Nov 05, 1998
United States of America 5908621 Jun 01, 1999
United States of America 6461605 Oct 08, 2002
United States of America 6524570 Feb 25, 2003
Slovakia 149199 Nov 07, 2000
Country Patent Number Publication Date

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Covington
Chubb
Chinese Patent Office
Fish and Richardson
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.